发明名称 |
CO-USE OF A CLUSTERIN INHIBITOR WITH AN EGFR INHIBITOR TO TREAT CANCER |
摘要 |
<p>Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.</p> |
申请公布号 |
EP2817028(A4) |
申请公布日期 |
2015.11.04 |
申请号 |
EP20130751181 |
申请日期 |
2013.02.22 |
申请人 |
ALETHIA BIOTHERAPEUTICS INC. |
发明人 |
TREMBLAY, GILLES BERNARD;VIAU, ELISABETH;FILION, MARIO |
分类号 |
A61K39/395;A61K31/506;A61K31/517;A61K31/5377;A61K39/00;A61K45/06;A61P35/00;C07K16/18;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|